Delving into the Latest Updates on Wuhan Wuyao Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Neoplasms

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Nervous System Diseases	2
Infectious Diseases	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

rpoB(DNA-directed RNA polymerase beta chain)	1
α1A-AR x α1B-AR	1
DNA	1

Bicalutamide tablets were prepared, comparing with the quality of reference list drug Casodex in laboratoryRelated substance was selected as evaluation of the types of adjuvant, the types of the disintegrating agent were confirmed through dissolution curve, the concentration of adhesive, the amount and the addition method of disintegrating agent and the amount of lubricant were studied through orthogonal design.The type of Opadry was researched through stress conditions.The final formulation can be used in pilot production

Guangzhou Huagong

One Pot Synthesis of Imatinib

Author: Yao Tong

One pot method is widely used in the synthesis of APIs.The traditional synthesis method of imatinib needs to prepare imatinic acid acyl chloride solid first, and then react with imatinic amime, which is not easy to operate in the production for the toxicity of acyl chloride.One pot method was used to solve the problem that acyl chloride was not easy to store and decomposeThe traditional two-step reaction was changed into one-step reaction, which simplified the operation steps, reduced the production cost and was more conducive to the process productionThe effects of the kinds of chlorination agents, the ratio of materials, the solvents and the temperature on the reaction were investigated.The optimum conditions for the synthesis of imatinib were obtained.

Guangzhou Huagong

A new method of synthesized dibenzothiazole disulfide

Author: Wang, Yin ; Wang, Xiu-jun ; Di, Zhen-xue ; Chen, Long ; Liang, Hua-liang ; Yang, Ming-li

The dibenzothiazyl disulfide (accelerator DM) was first synthesized with 2-mereapto benzothiazole (accelerator M), fuming nitric acid and glacial acetic acid by one step.The effects of the reactions temperature, the reaction time, and the mass ration yield were discussed.The optimal reaction conditions established were that the reaction temperature was 20°C, the ration of accelerator and glacial acetic was 1:20, the reaction was time was 40 min, and the ration of fuming nitric acid and accelerator M was 2:1.Under above conditions, the yield of accelerator DM was 92.4% and the m.p. was 169.6-171.0°C.

100 Deals associated with Wuhan Wuyao Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Wuhan Wuyao Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

5

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ethambutol Hydrochloride ( rpoB )	Tuberculosis More	Approved
Methoxsalen ( DNA )	Vitiligo More	Approved
Pirenoxine	Cataract More	Approved
Aminophenazone	Inflammation More	Approved
Norepinephrine Bitartrate ( α1A-AR x α1B-AR )	Hypotension More	Approved